Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF- β/SMAD pathway
In this study, we assessed the efficacy of Pirfenidone (PFD), an FDA-approved medication for the treatment of idiopathic pulmonary fibrosis, on TNBC cells as well as its anti-tumour effects in xenograft tumour model. PFD inhibited in a dose-dependent manner breast cancer cell proliferation, migration, and invasion, while promoted their apoptosis in vitro. PFD also suppressed TGF-β-induced activation of Smad signalling pathway and expression level of EMT-inducing transcription factors (e.g. SNAI2, TWIST1, ZEB1) as well as the mesenchymal genes such as VIMENTIN and N-Cadherin. On the contrary, the expression level of epithelial marker gene E-Cadherin was up-regulated in the presence of PFD. In vivo, PFD alone exerted a milder but significant anti-tumour effect than the chemotherapy drug nanoparticle albumin-bound paclitaxel (nab-PTX) did in the breast cancer xenograft mouse model. Interestingly, PFD synergistically boosted the cancer-killing effect of nab-PTX. Furthermore, Our data suggest that PFD suppressed breast cancer metastasis by inhibiting the activity of the TGFβ/SMAD pathway.PMID:36651490 | DOI:10.1111/jcmm.17673
Source: J Cell Mol Med - Category: Molecular Biology Authors: Daiqin Luo Xianlin Zeng Shuling Zhang Daohong Li Zhimei Cheng Yun Wang Jinhua Long Zuquan Hu Shiqi Long Jing Zhou Shuai Zhang Zhu Zeng Source Type: research
More News: Abraxane | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Epithelial Cancer | Genetics | Molecular Biology | Nanotechnology | Study